Sophia Genetics sees FY25 revenue $72M-$76M, consensus $74.51M

Sees FY25 adjusted EBITDA loss $35M-$39M. Camblong added, “Looking forward to 2025, we are well positioned to reaccelerate growth. Catalysts for the year include the new Liquid Biopsy application MSK-ACCESS powered with SOPHiA DDM which has already attracted 34 customers since its launch in Q2, exciting opportunities in the U.S., and an impressive base of 92 new customers to onboard and expand over the course of the year.”